125 Cambridgepark Dr, Suite 301
02140 Cambridge, us
FGen GmbH is coming to America – supported by INNOWWIDE Horizon 2020 and CYTO Consulting
FGen is expanding its world-leading microbial strain development services to US customers(PresseBox) ( Basel, Switzerland, )
FGen recently received a prestigious INNOWWIDE Horizon 2020 grant and is planning on using the proceeds to drive the US commercialization strategy.
Andreas Meyer, CEO and founder of FGen mentions: “After seeing an enormous success in the European market and seeing a significant interest from US clients, we feel the time is right to offer our market leading strain development services in a more systematic manner to US clients. We have been in contact with CYTO Consulting since early 2018, and we have had several very good meetings together. When INNOWWIDE launched its first call for proposals in April 2019, we reached out to CYTO Consulting to seek their support and to call for a partnership. They provided us with a project proposal as well as a letter of intent in order to support our INNOWWIDE Horizon 2020 European grant application. We are very happy that FGen was one of the few selected recipients of the funds, and we are now in a much better position for expanding decisively into the US market. Initially, CYTO Consulting will help us with local market research and business development activities. However, we have also started discussing the creation of a US subsidiary, the hiring of US personnel and the creation of a Boston-based service laboratory. We are excited about bringing our innovative Nanoliter Reactor Platform (NLR) to US customers to allow for faster microbial strain development at a lower cost and with a superior bio-production performance.”
CYTO Consulting is equally excited to collaborate with FGen on this project.
“We see a lot of very cutting-edge technologies in our line of work,” Odilo Mueller, president of CYTO Consulting states. “FGen’s approach to bio-engineering new microbial strains is among the most promising ones we have seen. Their nanoreactor-based approach to microbial strain development is superior to what is currently on the market and will have a big impact on the bioprocessing space. No wonder they were ahead of the competition in getting the prestigious Horizon 2020 grant. We are looking forward to helping them succeed in the US market.”
“Working with FGen exemplifies what we do best,” adds Mike Steyer, FGen project lead and senior partner at CYTO Consulting. “We take a successful product or service, develop a commercialization strategy fitting the US market, fill in knowledge gaps through market research, and then execute the strategy helping our clients to generate the first revenues in the new market.”
About FGen GmbH
FGen is an emerging Swiss biotech company focusing on the development and optimization of microbes for industrial biotechnology, food and feed, and agriculture. The combination of biological engineering, such as synthetic biology or non-GMO methods, with a proprietary high throughput screening platform enables a unique and efficient way to design bacteria, yeasts, and fungi with superior performance. FGen collaborates as contract research organization with partners from industrial biotech, life sciences, and pharma to improve existing or develop new bioproducts.
INNOWWIDE – Viability assessment of collaborative and INNOvative business solutions in WorldWIDE markets, is a Horizon 2020 project that aims to fund at least 120 European innovative SMEs and start-ups to conduct Viability Assessment Projects (VAPs) in markets outside of Europe.
The Coordination and Support Action INNOWWIDEH2020 was launched in Madrid on 10 January 2019. To compete effectively in new and emerging markets, European companies and especially SMEs need to develop partnerships with innovation players in these economies from early on and develop receptiveness for local success.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an email@example.com.